Mayo Clinic and Alexandria Venture Investments contributed to a $55m extension that boosted the molecular drug developer's overall funding to $143m.
US-based molecular therapeutics startup Senda Biosciences has completed a $98m series B round that included medical care and research provider Mayo Clinic.
The $55m close included Alexandria Venture Investments, the venture capital arm of life sciences real estate investment trust Alexandria Real Estate Equities, as well as founding Senda investor Flagship Pioneering and State of Michigan Retirement System, all existing investors.
Mayo Clinic and fellow new investors Longevity Vision Fund, Terra Magnum Capital Partners, Partners Investment and Mint Venture Partners…
